BG64457B1 - Фармацевтична форма за орално приложение, съдържаща hiv протеазен инхибитор - Google Patents

Фармацевтична форма за орално приложение, съдържаща hiv протеазен инхибитор Download PDF

Info

Publication number
BG64457B1
BG64457B1 BG102838A BG10283898A BG64457B1 BG 64457 B1 BG64457 B1 BG 64457B1 BG 102838 A BG102838 A BG 102838A BG 10283898 A BG10283898 A BG 10283898A BG 64457 B1 BG64457 B1 BG 64457B1
Authority
BG
Bulgaria
Prior art keywords
water
compound
tpgs
formula
formulation
Prior art date
Application number
BG102838A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102838A (en
Inventor
Arup Roy
Lloyd Tillman
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of BG102838A publication Critical patent/BG102838A/xx
Publication of BG64457B1 publication Critical patent/BG64457B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG102838A 1996-03-22 1998-10-12 Фармацевтична форма за орално приложение, съдържаща hiv протеазен инхибитор BG64457B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
BG102838A BG102838A (en) 1999-09-30
BG64457B1 true BG64457B1 (bg) 2005-03-31

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102838A BG64457B1 (bg) 1996-03-22 1998-10-12 Фармацевтична форма за орално приложение, съдържаща hiv протеазен инхибитор

Country Status (12)

Country Link
JP (1) JP3117726B2 (ja)
AR (1) AR006345A1 (ja)
BG (1) BG64457B1 (ja)
CO (1) CO4790151A1 (ja)
HU (1) HU228026B1 (ja)
ID (1) ID16781A (ja)
IL (1) IL126185A (ja)
MY (1) MY126358A (ja)
OA (1) OA10880A (ja)
PL (1) PL187919B1 (ja)
TW (1) TW455491B (ja)
WO (1) WO1997035587A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (es) * 1997-12-04 2000-10-16 Univ Granada Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
WO2002051414A1 (fr) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Compositions médicinales s'administrant par voie orale
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
JP2006518380A (ja) 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション 固体分散体組成物
ATE533473T1 (de) * 2004-09-24 2011-12-15 Boehringer Ingelheim Pharma Neue klasse von surfuctantähnlichen materialien mit vitamin-e-tpgs und wasserlöslichem polymer
JP2008514714A (ja) * 2004-09-30 2008-05-08 イーストマン ケミカル カンパニー 有意な流出阻害を示さない、親油性薬物を可溶化するビタミンｅｔｐｇｓ分子を含む医薬製剤及びこのような医薬製剤の使用
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
EP0541168A1 (en) * 1991-11-08 1993-05-12 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
WO1994005639A1 (en) * 1992-09-08 1994-03-17 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of hiv-aspartyl protease
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
WO1994014436A1 (en) * 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds
WO1994015906A1 (en) * 1993-01-15 1994-07-21 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors and their preparation
WO1995009843A1 (en) * 1993-10-07 1995-04-13 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
WO1995014016A1 (en) * 1993-11-18 1995-05-26 Merck & Co., Inc. Prodrugs of an inhibitor of hiv protease
WO1995016688A1 (en) * 1993-12-15 1995-06-22 Merck & Co., Inc. Hiv protease inhibitors
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
WO1995032185A1 (en) * 1994-05-23 1995-11-30 Agouron Pharmaceuticals, Inc. N-(3-amino-2-hydroxybutyl)sulphonamide derivatives as hiv protease inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
WO1996036316A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
EP0541168A1 (en) * 1991-11-08 1993-05-12 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
WO1994005639A1 (en) * 1992-09-08 1994-03-17 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of hiv-aspartyl protease
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
WO1994014436A1 (en) * 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds
WO1994015906A1 (en) * 1993-01-15 1994-07-21 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors and their preparation
WO1995009843A1 (en) * 1993-10-07 1995-04-13 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
WO1995014016A1 (en) * 1993-11-18 1995-05-26 Merck & Co., Inc. Prodrugs of an inhibitor of hiv protease
WO1995016688A1 (en) * 1993-12-15 1995-06-22 Merck & Co., Inc. Hiv protease inhibitors
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
WO1995032185A1 (en) * 1994-05-23 1995-11-30 Agouron Pharmaceuticals, Inc. N-(3-amino-2-hydroxybutyl)sulphonamide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
HUP9901887A3 (en) 2000-02-28
OA10880A (en) 2001-10-11
HUP9901887A2 (hu) 1999-12-28
IL126185A (en) 2003-05-29
BG102838A (en) 1999-09-30
ID16781A (id) 1997-11-13
PL328916A1 (en) 1999-03-01
MY126358A (en) 2006-09-29
CO4790151A1 (es) 1999-05-31
AR006345A1 (es) 1999-08-25
IL126185A0 (en) 1999-05-09
TW455491B (en) 2001-09-21
WO1997035587A1 (en) 1997-10-02
PL187919B1 (pl) 2004-11-30
JP2000500504A (ja) 2000-01-18
JP3117726B2 (ja) 2000-12-18
HU228026B1 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
ES2236891T3 (es) Sistemas binarios hidrofilos para la administracion de ciclosporina.
US20020077328A1 (en) Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
US6730679B1 (en) Pharmaceutical formulations
BG64457B1 (bg) Фармацевтична форма за орално приложение, съдържаща hiv протеазен инхибитор
KR100484695B1 (ko) 제약 조성물
EP0906107B1 (en) Compositions comprising vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
KR102301743B1 (ko) 에피나코나졸 경구용 조성물
KR100472581B1 (ko) Vx478과같은hiv프로테아제억제제및비타민e-tpgs와같은수용성비타민e화합물을포함하는조성물
WO2021245700A2 (en) Pharmaceutical lipid compositions of remdesivir
JP2003521495A (ja) テルビナフィン含有医薬組成物
US7632853B2 (en) Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof
KR20140100170A (ko) 셀레콕시브 경구투여용 조성물
US20060141028A1 (en) Cyclosporin formulations
UA67723C2 (en) Pharmaceutical formulations for peroral administration and method for its preparation
AU2010338249B2 (en) Oral liquid pharmaceutical composition of nifedipine
US20060217320A1 (en) Soft gel formulations for saquinavir
JP2011504162A (ja) 経口投与用チプラナビルの自己乳化型製剤